Human Papillomavirus Vaccine Frequency for University of Kansas Medical Center Pediatric Patients

Resumen

Background. Human papillomavirus (HPV) vaccination is recommended
for all adolescents aged 11 to 12 years, but coverage
in Kansas is exceptionally poor. To understand local coverage, receipt
of the 3-dose HPV vaccine series among pediatric patients at
the University of Kansas Medical Center (KUMC) was evaluated.

Methods. All patients aged 11 to 12 years who were seen by a
KUMC primary care provider (family medicine and pediatrics)
in 2013 were included in the retrospective chart review. Records
were reviewed through December 31, 2014 to capture the number
of HPV doses received, and receipt of other recommended
vaccines (tetanus-diphtheria-pertussis and meningococcal conjugate).
Pearson’s chi-squared tests were used to evaluate relationships
between HPV vaccination and patient characteristics.

Results. Of the 261 eligible females and 243 eligible males, 71.2%
received ≥ 1 HPV vaccine dose, 55.2% received ≥ 2 doses, and
39.3% completed the HPV vaccine series (3 doses). Although vaccine
initiation was slightly lower in males compared to females
(67.1% vs. 75.1%, p = 0.047), no difference in vaccine completion
was seen between males and females (37.0% vs. 41.7%, p = 0.319).
Over 80% of patients received other concurrently recommended
vaccines (Tdap: 81.7%, meningococcal: 81.3%). HPV series completion
occurred more often among Spanish-speaking females
compared to English-speaking females (59.5% vs 37.7%; p < 0.01).
Conclusions. The proportion of adolescents who received the
HPV vaccination at KUMC is substantially higher than national
and state estimates, but there is room for improvement for
both initiation and series completion. KS J Med 2016;9(1):1-5.